Antibe Therapeutics Price to Book Ratio 2014-2021 | ATBPF

Historical price to book ratio values for Antibe Therapeutics (ATBPF) over the last 10 years. The current price to book ratio for Antibe Therapeutics as of October 26, 2021 is 0.58.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Antibe Therapeutics Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
0.00 nan
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.034B $0.008B
Antibe Therapeutics Inc. is a biotech company with a drug platform of therapeutics in pain and inflammation. Its lead drug candidate consists of ATB-346, non-addictive drug for chronic pain and inflammation; ATB-352, for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. Antibe Therapeutics Inc. is based in Toronto, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86